000			nab a22 7a 4500
999			_c16606 _d16606
003			PC16606
005			20211015123420.0
008			211015b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92687 _aDiéguez Pastor, Mª Carmen _eAlergología
245	0	0	_aQUality Administration of SLIT in Allergic Rhinitis. SLIT: indications, follow-up, and management. _h[artículo]
260			_bJournal of investigational allergology & clinical immunology, _c2014
300			_a24 Suppl 1:1-35.
500			_aFormato Vancouver: Dávila I, Navarro A, Domínguez Ortega J, Alonso A, Antolín Amérigo D, Diéguez MC et al; QUASAR Group; QUality Administration of SLIT in Allergic Rhinitis. SLIT: indications, follow-up, and management. J Investig Allergol Clin Immunol. 2014;24 Suppl 1:1-35.
501			_aPMID: 25011377
504			_aContiene 266 referencias
520			_aSpecific sublingual immunotherapy (SLIT) has been proved to be a safe and effective approach in respiratory allergy. However, further research is required on aspects such as patient selection, use of optimal dosing, effects on asthma, long-term effects, and management of adverse reactions. In addition, the widely heterogeneous nature of studies on SLIT performed to date and the application of the criteria for subcutaneous immunotherapy make it difficult for the prescribing clinician to draw accurate and useful conclusions. Therefore, the QUASAR Group (QUality in the Administration of SLIT in Allergic Rhinitis), which comprises allergologists with broad clinical experience in SLIT, investigated the latest research findings and available data on this approach. Working parties were formed in 3 different categories: selection of candidates for SLIT, treatment efficacy, and adverse reactions. We performed a PubMed search for articles that were representative of each category and found 850. From these, we finally selected 266 articles, which were reviewed to retrieve data on SLIT. Evidence for each clinical question was graded according to the Oxford classification. The resulting text was evaluated on 3 occasions by all the members of the group until the final version was agreed upon. In this version, we review available evidence on SLIT, particularly with pollens, which is the subject of most articles. In areas where evidence is insufficient, an alternative agreed upon by the members of the QUASAR group is presented. Finally, we propose algorithms for selecting candidates for SLIT and for management of adverse events.
710			_999 _aServicio de Alergología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16606.pdf _ySolicitar documento,
942			_2ddc _cART _n0